Feature | November 07, 2013

LIA software proven to detect lead failures more frequently than impedance alone on Riata, Durata and Endotak Leads

November 7, 2013 — Medtronic Inc. announced U.S. Food and Drug Administration (FDA) approval of its Lead Integrity Alert (LIA) software for use with non-Medtronic leads. Proprietary and exclusive software that resides in Medtronic defibrillators, LIA is now approved to report performance issues on Durata and Riata defibrillator leads (St. Jude Medical) and Endotak (Boston Scientific) defibrillator leads when connected to a Medtronic device.
 
Originally approved by the FDA in 2008 for use with Medtronic defibrillators and leads, LIA has displayed the ability to detect pace/sense lead issues in non-Medtronic leads at a greater rate than standard impedance monitoring alone, according to an analysis recently published in Circulation: Arrhythmia and Electrophysiology.  For Durata and Riata leads (St. Jude Medical), LIA software detected pace/sense circuit issues approximately six times more frequently than with impedance monitoring.  The software detected pace/sense circuit issues more frequently for Endotak (Boston Scientific) leads as well.
 
"This approval affirms the applicability of Medtronic's LIA-enabled defibrillators in detecting lead issues in those leads developed by other manufacturers," said Kenneth Ellenbogen, M.D., Kontos Professor of Cardiology, Virginia Commonwealth University (VCU) School of Medicine and Medical College, Virginia Hospital.
 
In the United States, approximately 12,000 Medtronic LIA-enabled defibrillators (implantable cardioverter defibrillators (ICDs) and cardiac resynchronizationtherapy devices (CRT-Ds)) are connected to non-Medtronic leads, as identified and monitored remotely via the Medtronic CareLink Network. This includes approximately 5,100 Endotak leads, 6,100 Riata/Durata leads from St. Jude Medical and nearly 500 leads from other manufacturers, including Biotronik. An external panel of physicians who had access to device-stored electrograms and the clinical interpretation of the treating physician adjudicated non-Medtronic lead issues identified by LIA.
 
"We've seen the effectiveness of the LIA software with Medtronic devices and leads these past four years, and we know it can have an impact beyond our leads," said Marshall Stanton, M.D., vice president, Medtronic. "LIA detects lead failures better than impedance alone and this approval provides implanting physicians with performance information on this advanced decision-making tool to benefit the health and well-being of their patients."
 
LIA is included in the SmartShock suite of algorithms that yields the lowest occurrence rate of inappropriate shocks for any defibrillator in the industry. [i] [ii]
 
For more information: www.medtronic.com
 
References:
[i] Schloss EJ, et al. PainFree SST Trial Primary Results:  Low Shock Rates in Patients with Dual and Triple Chamber ICDs Using Novel Detection Algorithms. Heart Rhythm. 2013;10(50):S64.
[ii] Schloss E, et al. PainFree SmartShock technology: trial primary results: inappropriate shock rates in patients with single chamber ICD's using a novel suite of detection algorithms. EHRA Europace 2013 Late Breaking Trial session 1. 
 

Related Content

Itrevia 7 HF-T QP, Biotronik, CRT-D, first U.S. implantations, CLS algorithm
Feature | Cardiac Resynchronization Therapy Devices (CRT)| July 28, 2015
Biotronik announced the first patients have been successfully implanted with Itrevia HF-T QP cardiac resynchronization...
Feature | Atrial Fibrillation| July 20, 2015
A new study proves race and gender-related disparities exist in care for patients who have recently been diagnosed with...
Medtronic, Reveal Linq ICM, in-office insertion, RIO 2 study
News | Implantable Cardiac Monitor (ICM)| July 16, 2015
Medtronic plc announced the first in-office implant of its miniaturized cardiac monitor as part of the Medtronic Reveal...
Feature | Business| July 08, 2015
Sorin S.p.A. and Cyberonics Inc. unveiled LivaNova as the name of their combined company, effective at the close of...
Biosense Webster, Confidense Module, Carto, multi-electrode mapping, 3-D

Carto 3 System image courtesy of Biosense Webster

Technology | July 07, 2015
Biosense Webster Inc. announced the launch of the Confidense Module, an innovative technology that streamlines the...
idarucizumab, dabigatran, anticoagulant, Boehringer Ingelheim, RE-VERSE AD
News | Antiplatelet and Anticoagulation Therapies| July 07, 2015
Results from an interim analysis of the Phase III RE-VERSE AD patient study demonstrate that 5 g of idarucizumab...
Boston Scientific, Emblem, S-ICD, UNTOUCHED study, TV-ICDs, MADIT-RIT study
Feature | Implantable Cardioverter Defibrillators (ICD)| July 02, 2015
Boston Scientific has initiated a worldwide study to evaluate the rate and causes of shocks for patients implanted with...
Medtronic, CardioInsight, acquisition, ECVUE, cardiac mapping system

Image courtesy of CardioInsight Technologies Inc.

Feature | EP Mapping and Imaging Systems| July 01, 2015
Medtronic has acquired CardioInsight Technologies Inc., a Cleveland-based medical device company that has developed a...
ACC, HRS, SCAI, left atrial appendage occlusion, recommendations
Feature | Left Atrial Appendage (LAA) Occluders| June 30, 2015
The American College of Cardiology (ACC), Heart Rhythm Society (HRS) and Society for Cardiovascular Angiography and...
Overlay Init